Mounjaro®
Starting from £179.99/mo
Start journey Learn moreMost people notice reduced appetite within the first one to four weeks of starting Wegovy, but meaningful weight loss typically becomes visible after eight to twelve weeks. Measurable results — often 5% or more of body weight — build over months, not days, because the dose escalates gradually and the body adapts at its own pace. Wegovy (semaglutide) is a prescription-only medicine, and how quickly it works varies from person to person depending on starting dose, lifestyle changes and individual biology. A prescriber assesses whether it is clinically appropriate before any treatment begins.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The honest answer is: sometimes, yes. Many people report a noticeable drop in appetite (feeling fuller sooner at meals, less drawn to snacking) within the first one to four weeks of starting Wegovy. That is the GLP-1 receptor activity beginning to slow gastric emptying and reduce hunger signals. It can feel quite striking at first, which is reassuring if you have been waiting to see something happen.
What you are less likely to see in those early weeks is significant movement on the scales. Wegovy starts at 0.25 mg, a dose designed to let your digestive system adjust rather than to drive weight loss directly. The timeline for semaglutide to work is closely tied to how quickly your prescriber moves you up through the dose schedule, which is usually at four-weekly intervals. Weight loss in the first month tends to be modest (typically one to three kilograms) and that is entirely expected. Nausea and other gastrointestinal effects are most common at this stage, and they generally ease as your body settles.
It is worth knowing that side effects and efficacy are linked: the dose increments exist precisely to make the medicine tolerable, so patience during titration is not wasted time. If you are finding the early weeks difficult, that is a very common experience.
Most people see a clearer downward trend between weeks eight and sixteen, as the dose moves through 1.0 mg toward 1.7 mg. By around three months in, a 5% reduction in starting body weight is a reasonable benchmark for many patients. That is also the point at which clinical teams tend to assess whether the treatment is producing a meaningful response.
The full picture comes into view at the maintenance dose. In the STEP 1 trial (68 weeks, just over 1,900 adults with obesity or overweight plus at least one weight-related condition) participants on the 2.4 mg weekly dose lost an average of around 15% of their body weight compared with around 2.4% on placebo, as published in the New England Journal of Medicine. Those are averages; some participants lost considerably more, others less. The relationship between Wegovy's dose and weight-loss rate is not linear, results tend to compound once the maintenance dose is stable.
Newer data on the 7.2 mg maintenance dose reports approximately 20.7% average weight loss over 72 weeks, bringing it closer to tirzepatide's results. A dedicated single-dose 7.2 mg pen was approved by the MHRA in April 2026. Whether any specific dose or pen format is suitable for you is a clinical decision, not one the dose number alone answers.
Six months is a formal checkpoint. Under NICE guidance on semaglutide (TA875), if someone has not achieved at least 5% weight loss after six months on the highest tolerated maintenance dose, continuing treatment is reviewed. This is not a pass-or-fail moment designed to discourage people; it exists because the medicine works well for most but not all, and clinical resources should follow the evidence. If you are on a private prescription, your prescriber applies the same clinical logic.
People who are still at lower doses at the six-month mark (because titration moved more slowly, or because side effects required pausing) should not compare themselves against this benchmark as if they were already at maintenance dose. Timeline is individual, and if you want a clearer sense of what to expect at each stage, our guide on how long it takes for Wegovy to start working walks through the dose-by-dose picture in detail.
The NHS also notes on its weight management injections guidance that lifestyle changes (a reduced-calorie diet and increased physical activity) sit alongside the medicine throughout; results are strongest when both are in place. That is not a caveat to soften expectations, it is how the treatment was designed to work.
Weight loss with Wegovy does tend to plateau. For most people, the curve flattens somewhere between nine and eighteen months at maintenance dose, not because the medicine has stopped working but because the body reaches a new equilibrium. Appetite suppression continues; maintaining the lower weight requires continued treatment in most cases, and if you are curious about how long Wegovy takes to work at each stage of that journey, the answer varies more than many people expect. Long-term evidence shows that weight tends to return if the medicine is stopped without lifestyle changes firmly in place, a pattern seen clearly in extension data from the STEP trials.
This is a meaningful consideration for anyone weighing up a private prescription. The cost of ongoing treatment adds up, and that is worth factoring in honestly. You can explore what affects the cost of Wegovy in the UK for a clear-eyed look at what is included in a legitimate private prescription price. The clinical team at our GPhC-registered pharmacy reviews each repeat order individually before it is dispatched, which means there is no automatic continuation, and no automatic stopping either.
If you are thinking about starting treatment or have questions about where you are in the process, starting a free consultation puts your questions in front of a GPhC-registered prescriber, not a chatbot.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.